valproic acid has been researched along with Lennox Gastaut Syndrome in 13 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Lennox Gastaut Syndrome: A childhood-onset epilepsy syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome." | 9.14 | Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. ( Balestri, A; Capovilla, G; Coppola, G; Curatolo, P; Fels, A; Franzoni, E; Grosso, S; Habetswallner, F; Mangano, S; Parisi, P; Pascotto, A; Spalice, A; Veggiotti, P; Verrotti, A; Zamponi, N, 2010) |
| " Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older." | 9.12 | Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. ( García-Peñas, JJ; Gil Nagel-Rein, A; Sánchez-Carpintero, R; Villanueva-Haba, V, 2021) |
| "Here, we present a multicenter series of patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox-Gastaut syndrome (LGS) who were treated with rufinamide as add-on therapy." | 7.96 | Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients. ( Caraballo, RH; Espeche, A; Fasulo, L; Galichio, S; Pociecha, J; Reyes, G; Semprino, M, 2020) |
| "In January 2019, a new plant-derived purified cannabidiol preparation, approved by the US Food and Drug Administration, became commercially available for patients ≥2 years old with Lennox-Gastaut syndrome or Dravet syndrome." | 7.96 | Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid. ( Carlson, M; Dang, LT; Fedak Romanowski, EM; Joshi, SM; Leber, SM; McNamara, NA; Robertson, P; Shellhaas, RA; Smith, GC; Sturza, J; Ziobro, JM, 2020) |
| "This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome." | 5.14 | Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. ( Balestri, A; Capovilla, G; Coppola, G; Curatolo, P; Fels, A; Franzoni, E; Grosso, S; Habetswallner, F; Mangano, S; Parisi, P; Pascotto, A; Spalice, A; Veggiotti, P; Verrotti, A; Zamponi, N, 2010) |
| " Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older." | 5.12 | Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. ( García-Peñas, JJ; Gil Nagel-Rein, A; Sánchez-Carpintero, R; Villanueva-Haba, V, 2021) |
| "Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut syndrome or Dravet syndrome in randomized, double-blind, add-on, controlled phase 3 trials." | 5.05 | Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. ( Critchley, D; Gidal, B; Morrison, G; Patsalos, PN; Szaflarski, JP; VanLandingham, K, 2020) |
| "Here, we present a multicenter series of patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox-Gastaut syndrome (LGS) who were treated with rufinamide as add-on therapy." | 3.96 | Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients. ( Caraballo, RH; Espeche, A; Fasulo, L; Galichio, S; Pociecha, J; Reyes, G; Semprino, M, 2020) |
| "In January 2019, a new plant-derived purified cannabidiol preparation, approved by the US Food and Drug Administration, became commercially available for patients ≥2 years old with Lennox-Gastaut syndrome or Dravet syndrome." | 3.96 | Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid. ( Carlson, M; Dang, LT; Fedak Romanowski, EM; Joshi, SM; Leber, SM; McNamara, NA; Robertson, P; Shellhaas, RA; Smith, GC; Sturza, J; Ziobro, JM, 2020) |
| " The aim of our study was to analyze the effect of age, gender, daily RUF dose per body weight (mg/kg), valproic acid (VPA), and enzyme-inducing antiepileptic drugs (EIAEDs) on RUF concentration-to-dose ratio (RUF serum concentration/RUF dose per body weight), RUF clearance (RUF dose/RUF serum concentration), and RUF trough concentrations." | 3.77 | Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. ( Boor, R; Brandt, C; Jürgens, U; Korn-Merker, E; May, TW; Rambeck, B, 2011) |
| "On VPA 1000 mg/d, the seizure frequency decreased significantly." | 1.37 | Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome. ( Crespel, A; Gelisse, P; Genton, P; Pageaux, GP; Velizarova, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| García-Peñas, JJ | 1 |
| Gil Nagel-Rein, A | 1 |
| Sánchez-Carpintero, R | 1 |
| Villanueva-Haba, V | 1 |
| Riva, A | 1 |
| Coppola, A | 1 |
| Bonaventura, CD | 1 |
| Elia, M | 1 |
| Ferlazzo, E | 1 |
| Gobbi, G | 1 |
| Marini, C | 1 |
| Meletti, S | 1 |
| Romeo, A | 1 |
| Santoro, K | 1 |
| Verrotti, A | 2 |
| Capovilla, G | 2 |
| Striano, P | 2 |
| Brigo, F | 1 |
| Belcastro, V | 1 |
| Caraballo, RH | 1 |
| Pociecha, J | 1 |
| Reyes, G | 1 |
| Espeche, A | 1 |
| Galichio, S | 1 |
| Fasulo, L | 1 |
| Semprino, M | 1 |
| McNamara, NA | 1 |
| Dang, LT | 1 |
| Sturza, J | 1 |
| Ziobro, JM | 1 |
| Fedak Romanowski, EM | 1 |
| Smith, GC | 1 |
| Joshi, SM | 1 |
| Leber, SM | 1 |
| Carlson, M | 1 |
| Robertson, P | 1 |
| Shellhaas, RA | 1 |
| Patsalos, PN | 1 |
| Szaflarski, JP | 1 |
| Gidal, B | 1 |
| VanLandingham, K | 1 |
| Critchley, D | 1 |
| Morrison, G | 1 |
| Ennaim, N | 1 |
| Bourrous, M | 1 |
| Rada, N | 1 |
| Draiss, G | 1 |
| Bouskraoui, M | 1 |
| Suzuki, K | 1 |
| Hiramoto, A | 1 |
| Okumura, T | 1 |
| Stevens, CE | 1 |
| Turner, Z | 1 |
| Kossoff, EH | 1 |
| Deng, XL | 1 |
| Yin, F | 1 |
| Zhang, CL | 1 |
| Ma, YP | 1 |
| He, F | 1 |
| Wu, LW | 1 |
| Peng, J | 1 |
| Coppola, G | 1 |
| Grosso, S | 1 |
| Franzoni, E | 1 |
| Veggiotti, P | 1 |
| Zamponi, N | 1 |
| Parisi, P | 1 |
| Spalice, A | 1 |
| Habetswallner, F | 1 |
| Fels, A | 1 |
| Mangano, S | 1 |
| Balestri, A | 1 |
| Curatolo, P | 1 |
| Pascotto, A | 1 |
| Velizarova, R | 1 |
| Gelisse, P | 1 |
| Pageaux, GP | 1 |
| Genton, P | 1 |
| Crespel, A | 1 |
| May, TW | 1 |
| Boor, R | 1 |
| Rambeck, B | 1 |
| Jürgens, U | 1 |
| Korn-Merker, E | 1 |
| Brandt, C | 1 |
4 reviews available for valproic acid and Lennox Gastaut Syndrome
| Article | Year |
|---|---|
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Clonazepam; Diazepam; Dioxolanes; Drug Administration Schedu | 2021 |
A reappraisal of atypical absence seizures in children and adults: therapeutic implications.
Topics: Anticonvulsants; Epilepsy, Generalized; Ethosuximide; Humans; Lamotrigine; Lennox Gastaut Syndrome; | 2019 |
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Topics: Anticonvulsants; Cannabidiol; Clinical Trials as Topic; Clobazam; Cytochrome P-450 CYP2C19; Cytochro | 2020 |
[Dynamin-1-related infantile spasms: a case report and review of literature].
Topics: Child; Child, Preschool; Developmental Disabilities; Dynamin I; Electroencephalography; Epilepsy; Fe | 2016 |
1 trial available for valproic acid and Lennox Gastaut Syndrome
| Article | Year |
|---|---|
Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Huma | 2010 |
8 other studies available for valproic acid and Lennox Gastaut Syndrome
| Article | Year |
|---|---|
An Italian consensus on the management of Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Consensus; Fenfluramine; Humans; Lamotrigine; Lennox Gastaut | 2022 |
Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
Topics: Adolescent; Anticonvulsants; Argentina; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy | 2020 |
Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
Topics: Adolescent; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Drug Resistant Epilepsy; Drug The | 2020 |
[Lennox-Gastaut syndrome: Experience of Marrakech University Hospital].
Topics: Accidental Falls; Anticonvulsants; Asphyxia Neonatorum; Atrophy; Cerebral Cortex; Child; Child, Pres | 2013 |
A case report on reversible Pelger-Huët anomaly depending on serum free fraction of valproic acid.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Humans; Hypoalbuminemia; Lennox Gastaut Syndrome; | 2015 |
Hepatic Dysfunction as a Complication of Combined Valproate and Ketogenic Diet.
Topics: Anticonvulsants; Combined Modality Therapy; Diet, Ketogenic; Drug Resistant Epilepsy; Female; Follow | 2016 |
Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Electroencephalography; Female; Fructose; H | 2011 |
Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Body Weight; Child; Child, Preschool; Dose-Response | 2011 |